This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Emerging Strategies to Delay Progression in Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

Emerging Strategies to Delay Progression in Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

Format

Expert Perspective

Time to Complete

1.25 hours

Released

August 31, 2018

Expires

August 31, 2019
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 CreditsTM

Accredited Provider



Provided by the National Kidney Foundation

Commercial Supporter

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Producer



Produced by Haymarket Medical Education

Program Description

Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited disorder that affects 1 to 2 individuals per 1000 worldwide. Morphological disorganization of renal tissue results in the hallmark disease process: development of large, fluid-filled cysts in the kidney, which over time increase kidney size and ultimately compromise kidney function. These changes typically begin insidiously, with few symptoms to alert patients that the damage is occurring. Patients exhibit urine concentration, pain, hypertension, kidney stones, hematuria, and infections; long-term sequelae include end-stage renal disease (ESRD) and cardiovascular complications, with 70% of patients developing ESRD at a median age of 58 years.

In this video, 2 experts in the management of ADPKD discuss the gamut of concerns in the management of ADPKD, from deciding which patients should be screened for ADPKD, how to identify patients at increased risk for severe disease and/or complications including extrarenal manifestations of ADPKD, and current standards of care to the role of new and emerging treatments that can delay the progression of ADPKD.

Intended Audience

Nephrologists, pediatric nephrologists, internists, family physicians, physician assistants, and nurse practictioners

Educational Objectives

After completing the activity, the participant should be better able to:

  • Identify patients with autosomal-dominant polycystic kidney disease (ADPKD) by recognizing the signs and symptoms of the disease and instituting a complete diagnostic workup
  • Plan a clinical strategy that aims to mitigate progression of ADPKD as much as possible with available, evidence-based modalities
  • Anticipate emerging therapies with vasopressin type 2 (V2) receptor antagonists that can delay progression in ADPKD through an understanding of ADPKD pathobiology, therapeutic targets, and recent clinical trials

Conflict Of Interest Disclosure Policies

It is the policy of the National Kidney Foundation (NKF) and Haymarket Medical Education to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity.

If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.

Faculty

Simin O. Goral, MD
Director, Polycystic Kidney Disease Clinic
Transplant Nephrology Fellowship Director
Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA

Dr. Goral receives grant support from Astellas, AstraZeneca, Kadmon Corporation, and Otsuka America Pharmaceutical, Inc.

Arlene B. Chapman, MD
Professor of Medicine
Director, Section of Nephrology
Department of Medicine
Director, Clinical Research Center
Institute for Translational Medicine
Biological Sciences Division
University of Chicago
Chicago, IL

Dr. Chapman receives consultant fees from Janssen; Otsuka America Pharmaceutical, Inc.; and Sanofi.

Planning Committee Disclosures

Jessica Joseph, MBA
Vice President, Scientific Activities
National Kidney Foundation
New York, NY

Ms. Joseph has no financial relationships with commercial interest(s).

Danielle Nathan, MA
Senior Director, Professional Education
National Kidney Foundation
New York, NY

Ms. Nathan has no financial relationships with commercial interest(s).

Margot Embree Fisher
Director, Grant and Content Development
Haymarket Medical Education
Paramus, NJ

Ms. Embree Fisher has no financial relationships with commercial interest(s).

Priya Wanchoo, MD, CHCP
Vice President and Medical Director
Haymarket Medical Education
Paramus, NJ

Dr. Wanchoo has no financial relationships with commercial interest(s).

Credit

1.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, the National Kidney Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education to the healthcare team.

Designation Statement

The National Kidney Foundation designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 Category 1 Credits for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM  from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

Disclaimer

The faculty, the National Kidney Foundation (NKF), and Haymarket Medical Education do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Information contained in this educational resource is based upon current data available at the time of publication. Information is intended to help clinicians become aware of new scientific findings and developments. This NKF/Haymarket Medical Education resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.

Instructions

Learners will review the materials on accreditation information, target audience, learning objectives, and disclosure information; complete the pre-test; review the video content; and complete the post-test (minimum score of 70% required; learners will only have 3 attempts to pass the post-test) and evaluation to successfully earn credit.

For any questions concerning the accreditation of this activity, please send an email to CMEinfo@kidney.org.

If you have any other questions relating to your certificate or other issues with the activity, please contact
myCME.Support@haymarketmedical.com.

Privacy Policy

To view the NKF privacy and confidentiality policy as it relates to this CME/CE activity, please visit http://www.kidney.org/.

For additional professional education resources, contact NKF at 1-800-622-9010 or visit https://www.kidney.org/professionals.

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue